Holen Sie sich die Stockscreener-App
2.92
2.99%
-0.09
Handel nachbörslich:
2.92
Schlusskurs vom Vortag:
$3.01
Offen:
$2.87
24-Stunden-Volumen:
276.71K
Relative Volume:
0.55
Marktkapitalisierung:
$143.34M
Einnahmen:
$230.47M
Nettoeinkommen (Verlust:
$30.28M
KGV:
4.7869
EPS:
0.61
Netto-Cashflow:
$38.86M
1W Leistung:
-7.30%
1M Leistung:
-12.84%
6M Leistung:
+15.87%
1J Leistung:
-45.42%
1-Tages-Spanne:
$2.835
$2.945
1-Wochen-Bereich:
$2.835
$3.175
52-Wochen-Spanne:
$2.225
$6.055
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Vergleichen Sie PBYI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
2.92 | 143.34M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
Puma Biotech Expands Team: New Hires Receive Strategic Stock Compensation Package - Stock Titan
Further weakness as Puma Biotechnology (NASDAQ:PBYI) drops 11% this week, taking five-year losses to 55% - simplywall.st
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 - BioSpace
Groundbreaking Clinical Trial: Neratinib's Novel Combination Approach Targets HER2 Tumors - Stock Titan
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why - Nasdaq
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - MSN
Why Investors Are Buzzing About Puma Biotechnology’s Earnings: Unpacking the Details - procarsrl.com.ar
Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now - MSN
Checking in on Puma Biotechnology Inc (PBYI) after recent insiders movement - Knox Daily
Rhumbline Advisers Lowers Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26% - Simply Wall St
Puma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.com - Armenian Reporter
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by StockNews.com - Defense World
We Think Puma Biotechnology's (NASDAQ:PBYI) Healthy Earnings Might Be Conservative - Yahoo Finance
Puma Biotech grants stock award to new hire By Investing.com - Investing.com Australia
Puma Biotechnology, Inc. to Host Earnings Call - ACCESS Newswire
Puma Biotechnology to Present at Barclays 27th Annual Global Healthcare Conference - BioSpace
Puma Biotech grants stock award to new hire - Investing.com India
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference - BioSpace
Can Puma Biotechnology's Conference Presentation Signal New Growth Opportunities? - StockTitan
Puma Biotechnology’s Earnings Call: Mixed Sentiments and Future Outlook - MSN
Puma Biotechnology’s (PBYI) Buy Rating Reiterated at HC Wainwright - Defense World
Results: Puma Biotechnology, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates - Nasdaq
Puma Biotechnology: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results - sharewise
Puma Biotechnology Reports Strong Earnings Growth in 2024 - TipRanks
Puma Biotech: Q4 Earnings Snapshot - CTPost
Puma Biotechnology: Hold Rating Amidst Flat Sales Growth and Uncertain Drug Prospects - TipRanks
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Puma Biotech Q4 2024 beats earnings expectations By Investing.com - Investing.com South Africa
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Earnings call transcript: Puma Biotech Q4 2024 beats earnings expectations - Investing.com
Puma Biotech stock rises as Q4 earnings surpass expectations By Investing.com - Investing.com Canada
Puma Biotech stock rises as Q4 earnings surpass expectations - Investing.com
Puma Biotechnology Boosts Profits 57% While Revenue Dips: What's Behind This Earnings Paradox? - StockTitan
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference - BioSpace
Puma Biotechnology Reveals Corporate Strategy at Major Healthcare ConferenceWhat Will CEO Disclose? - StockTitan
Puma Biotechnology Inc expected to post earnings of 10 cents a shareEarnings Preview - TradingView
Investors in Puma Biotechnology (NASDAQ:PBYI) have unfortunately lost 73% over the last five years - Yahoo Finance
Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday - Defense World
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):